Autopsy report · NCT04548791

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

“Company decision (not a safety issue)”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 7 months before it stopped.
• 19 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Catalyst Biosciences

Sponsor type

Industry

Conditions

Factor VII Deficiency; Glanzmann Thrombasthenia; Hemophilia A With Inhibitor

Interventions

Coagulation Factor VIIa variant

Participants

19

Sites

20

Countries

India, Italy, Russia, Ukraine, United States

Trials that died the same way

• Investigational Study of Delayed Release Metformin
  “Strategic company decision - not related to a safety concern” (83% match in meaning)
• Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
  “Business decision, not related to safety” (83% match in meaning)
• A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
  “Internal company decision (non-safety related)” (83% match in meaning)
• The KHENERGYC Study
  “Strategic company decision - not related to safety concerns” (83% match in meaning)
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants
  “internal company decision; not safety related” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.